BINV — BioInvent International AB Balance Sheet
0.000.00%
Last trade - 00:00
- SEK1.20bn
- SEK153.50m
- SEK71.46m
- 16
- 17
- 45
- 14
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 154 | 729 | 1,083 | 1,017 | 1,069 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 29.9 | 35.5 | 9.39 | 36.6 | 32.7 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Current Assets | 193 | 773 | 1,116 | 1,084 | 1,133 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 33 | 29.6 | 49.1 | 52 | 52.7 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Total Assets | 226 | 803 | 1,447 | 1,712 | 1,400 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 47.2 | 53.5 | 58.8 | 87.3 | 75.9 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Liabilities | 56.7 | 59.1 | 80.3 | 106 | 90.5 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 169 | 743 | 1,367 | 1,606 | 1,310 |
Total Liabilities & Shareholders' Equity | 226 | 803 | 1,447 | 1,712 | 1,400 |
Total Common Shares Outstanding |